215 related articles for article (PubMed ID: 30423192)
1. The antitumor effects of entinostat in ovarian cancer require adaptive immunity.
Smith HJ; McCaw TR; Londono AI; Katre AA; Meza-Perez S; Yang ES; Forero A; Buchsbaum DJ; Randall TD; Straughn JM; Norian LA; Arend RC
Cancer; 2018 Dec; 124(24):4657-4666. PubMed ID: 30423192
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
Turner TB; Meza-Perez S; Londoño A; Katre A; Peabody JE; Smith HJ; Forero A; Norian LA; Straughn JM; Buchsbaum DJ; Randall TD; Arend RC
Oncotarget; 2017 Jul; 8(27):44159-44170. PubMed ID: 28498806
[TBL] [Abstract][Full Text] [Related]
3. Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.
Gupta VG; Hirst J; Petersen S; Roby KF; Kusch M; Zhou H; Clive ML; Jewell A; Pathak HB; Godwin AK; Wilson AJ; Crispens MA; Cybulla E; Vindigni A; Fuh KC; Khabele D
Gynecol Oncol; 2021 Jul; 162(1):163-172. PubMed ID: 33867143
[TBL] [Abstract][Full Text] [Related]
4. A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.
Lee J; Bartholomeusz C; Mansour O; Humphries J; Hortobagyi GN; Ordentlich P; Ueno NT
Breast Cancer Res Treat; 2014 Jul; 146(2):259-72. PubMed ID: 24916181
[TBL] [Abstract][Full Text] [Related]
5. Class I histone deacetylase inhibitor entinostat suppresses regulatory T cells and enhances immunotherapies in renal and prostate cancer models.
Shen L; Ciesielski M; Ramakrishnan S; Miles KM; Ellis L; Sotomayor P; Shrikant P; Fenstermaker R; Pili R
PLoS One; 2012; 7(1):e30815. PubMed ID: 22303460
[TBL] [Abstract][Full Text] [Related]
6. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
7. HDAC inhibitor entinostat restores responsiveness of letrozole-resistant MCF-7Ca xenografts to aromatase inhibitors through modulation of Her-2.
Sabnis GJ; Goloubeva OG; Kazi AA; Shah P; Brodie AH
Mol Cancer Ther; 2013 Dec; 12(12):2804-16. PubMed ID: 24092810
[TBL] [Abstract][Full Text] [Related]
8. Cooperative Immune-Mediated Mechanisms of the HDAC Inhibitor Entinostat, an IL15 Superagonist, and a Cancer Vaccine Effectively Synergize as a Novel Cancer Therapy.
Hicks KC; Knudson KM; Lee KL; Hamilton DH; Hodge JW; Figg WD; Ordentlich P; Jones FR; Rabizadeh S; Soon-Shiong P; Schlom J; Gameiro SR
Clin Cancer Res; 2020 Feb; 26(3):704-716. PubMed ID: 31645354
[TBL] [Abstract][Full Text] [Related]
9. Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer.
McCaw TR; Goel N; Brooke DJ; Katre AA; Londoño AI; Smith HJ; Randall TD; Arend RC
Cancer Med; 2021 Jan; 10(2):709-717. PubMed ID: 33369199
[TBL] [Abstract][Full Text] [Related]
10. Entinostat for the treatment of breast cancer.
Trapani D; Esposito A; Criscitiello C; Mazzarella L; Locatelli M; Minchella I; Minucci S; Curigliano G
Expert Opin Investig Drugs; 2017 Aug; 26(8):965-971. PubMed ID: 28718331
[TBL] [Abstract][Full Text] [Related]
11. Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma.
Orillion A; Hashimoto A; Damayanti N; Shen L; Adelaiye-Ogala R; Arisa S; Chintala S; Ordentlich P; Kao C; Elzey B; Gabrilovich D; Pili R
Clin Cancer Res; 2017 Sep; 23(17):5187-5201. PubMed ID: 28698201
[TBL] [Abstract][Full Text] [Related]
12. Histone Deacetylase Inhibitor Entinostat Inhibits Tumor-Initiating Cells in Triple-Negative Breast Cancer Cells.
Schech A; Kazi A; Yu S; Shah P; Sabnis G
Mol Cancer Ther; 2015 Aug; 14(8):1848-57. PubMed ID: 26037781
[TBL] [Abstract][Full Text] [Related]
13. Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.
Frys S; Simons Z; Hu Q; Barth MJ; Gu JJ; Mavis C; Skitzki J; Song L; Czuczman MS; Hernandez-Ilizaliturri FJ
Br J Haematol; 2015 May; 169(4):506-19. PubMed ID: 25712263
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.
Pollack BP; Sapkota B; Cartee TV
Clin Cancer Res; 2011 Jul; 17(13):4400-13. PubMed ID: 21586626
[TBL] [Abstract][Full Text] [Related]
15. Entinostat induces antitumor immune responses through immune editing of tumor neoantigens.
Truong AS; Zhou M; Krishnan B; Utsumi T; Manocha U; Stewart KG; Beck W; Rose TL; Milowsky MI; He X; Smith CC; Bixby LM; Perou CM; Wobker SE; Bailey ST; Vincent BG; Kim WY
J Clin Invest; 2021 Aug; 131(16):. PubMed ID: 34396985
[TBL] [Abstract][Full Text] [Related]
16. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
17. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
[TBL] [Abstract][Full Text] [Related]
18. Preclinical rationale for entinostat in embryonal rhabdomyosarcoma.
Bharathy N; Berlow NE; Wang E; Abraham J; Settelmeyer TP; Hooper JE; Svalina MN; Bajwa Z; Goros MW; Hernandez BS; Wolff JE; Pal R; Davies AM; Ashok A; Bushby D; Mancini M; Noakes C; Goodwin NC; Ordentlich P; Keck J; Hawkins DS; Rudzinski ER; Mansoor A; Perkins TJ; Vakoc CR; Michalek JE; Keller C
Skelet Muscle; 2019 May; 9(1):12. PubMed ID: 31113472
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates HER2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer.
Schech AJ; Shah P; Yu S; Sabnis GJ; Goloubeva O; Rosenblatt P; Kazi A; Chumsri S; Brodie A
Breast Cancer Res Treat; 2015 Aug; 152(3):499-508. PubMed ID: 26133921
[TBL] [Abstract][Full Text] [Related]
20. [Major histocompatibility complex class II transactivator (CIITA) hammer- head ribozyme transfer inhibits major histocompatibility complex class II (MHC-II) expression in Jukart cells].
Guo R; Zou P; Song YP; Ma J; Lu HZ; Cao YL; Tong YJ
Zhonghua Er Ke Za Zhi; 2003 Dec; 41(12):925-8. PubMed ID: 14723817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]